Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study

Abstract

Background

Incidence and risk factors of HIV-associated non-Hodgkin's lymphoma (NHL) are not well defined in the era of combination antiretroviral therapy (cART).

Methods

A total of 56,305 adult HIV type-1 (HIV-1)-infected patients who started cART in 1 of 22 prospective studies in Europe were included. Weibull random effects models were used to estimate hazard ratios (HRs) for developing systemic NHL and included CD4⁺ T-cell counts and viral load as time-updated variables.

Results

During the 212,042 person-years of follow-up, 521 patients were diagnosed with systemic NHL and 62 with primary brain lymphoma (PBL). The incidence rate of systemic NHL was 463 per 100,000 person-years not on cART and 205 per 100,000 person-years in treated patients for a rate ratio of 0.44 (95% confidence interval [CI] 0.37–0.53). The corresponding incidence rates of PBL were 57 and 24 per 100,000 person-years (rate ratio 0.43, 95% CI 0.25-0.73). Suppression of HIV-1 replication on cART (HR 0.60, 95% CI 0.44-0.81, comparing ≤500 with 10,000-99,999 copies/ml) and increases in CD4⁺ T-cell counts (HR 0.30, 0.22-0.42, comparing ≥350 with 100-199 cells/pl) were protective; a history of Kaposi's sarcoma (HR 1.70, 1.08-2.68, compared to no history of AIDS), transmission through sex between men (HR 1.57, 1.19-2.08, compared with heterosexual transmission) and older age (HR 3.71, 2.37-5.80, comparing ≥50 with 16-29 years) were risk factors for systemic NHL.

Conclusions

The incidence rates of both systemic NHL and PBL were substantially reduced in patients on cART. Timely initiation of therapy is key to the prevention of NHL in the era of cART.

References

Dal Maso

, Franceschi

Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS.

Lancet Oncol 2003; 4: 110–119.

Frisch

, Biggar

R.J.

, Engels

E.A.

, Goedert

J.J.

Association of cancer with AIDS-related immunosuppression in adults.

JAMA 2001; 285: 1736–1745.

Cote

T.R.

, Biggar

R.J.

, Rosenberg

P.S.

Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group.

Int J Cancer 1997; 73: 645–650.

Ledergerber

, Egger

, Erard

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

JAMA 1999; 282: 2220–2226.

Engels

E.A.

, Biggar

R.J.

, Hall

H.I.

Cancer risk in people infected with human immunodeficiency virus in the United States.

Int J Cancer 2008; 123: 187–194.

Crum-Cianflone

, Hullsiek

K.H.

, Marconi

Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.

AIDS 2009; 23: 41–50.

Patel

, Hanson

D.L.

, Sullivan

P.S.

Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1993–200.

Ann Intern Med 2008; 148: 728–736.

The Antiretroviral Therapy Cohort Collaboration.

The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.

Arch Intern Med 2005; 165: 416–423.

Spano

J.P.

, Costagliola

, Katlama

, Mounier

, Oksenhendler

, Khayat

AIDS-related malignancies: state of the art and therapeutic challenges.

J Clin Oncol 2008; 26: 4834–4842.

10.

Bonnet

, Burty

, Lewden

Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey.

Clin Infect Dis 2009; 48: 633–639.

11.

Kirk

, Pedersen

, Cozzi-Lepri

Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.

Blood 2001; 98: 3406–3412.

12.

Stebbing

, Gazzard

, Mandalia

Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.

J Clin Oncol 2004; 22: 2177–2183.

13.

Polesel

, Clifford

G.M.

, Rickenbach

Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

AIDS 2008; 22: 301–306.

14.

Zoufaly

, Stellbrink

H.J.

, Heiden

M.A.

Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.

J Infect Dis 2009; 99: 79–87.

15.

Biggar

R.J.

, Chaturvedi

A.K.

, Goedert

J.J.

, Engels

E.A.

AIDS-related cancer and severity of immunosuppression in persons with AIDS.

J Natl Cancer Inst 2007; 99: 962–972.

16.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.

Response to combination antiretroviral therapy: variation by age.

AIDS 2008; 22: 1463–1473.

17.

Kjaer

, Ledergerber

HIV cohort collaborations: proposal for harmonization of data exchange.

Antivir Ther 2004; 9: 631–633.

18.

US Centers for Disease and Prevention.

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

MMWR Recomm Rep 1992; 41: 1–19.

19.

Engels

E.A.

, Rosenberg

P.S.

, Frisch

, Goedert

J.J.

Cancers associated with Kaposi's sarcoma (KS) in AIDS: a link between KS herpesvirus and immunoblastic lymphoma.

Br J Cancer 2001; 85: 1298–1303.

20.

Deloose

S.T.

, Smit

L.A.

, Pals

F.T.

, Kersten

M.J.

, van Noesel

C.J.

, Pals

S.T.

High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/ plasmablastic diffuse large B-cell lymphoma.

Leukemia 2005; 19: 851–855.

21.

Chadburn

, Hyjek

, Mathew

, Cesarman

, Said

, Knowles

D.M.

KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma.

Am J Surg Pathol 2004; 28: 1401–1416.

22.

Bonnet

, Balestre

, Thiebaut

Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.

Clin Infect Dis 2006; 42: 411–417.

23.

International Collaboration on HIV and Cancer.

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.

J Natl Cancer Inst 2000; 92: 1823–1830.

24.

Hoffmann

, Wolf

, Fatkenheuer

Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.

AIDS 2003; 17: 1521–1529.

25.

Antinori

, Cingolani

, Alba

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.

AIDS 2001; 15: 1483–1491.

26.

Simcock

, Blasko

, Karrer

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Antivir Ther 2007; 12: 931–939.

27.

Boue

, Gabarre

, Gisselbrecht

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

J Clin Oncol 2006; 24: 4123–4128.

28.

Grulich

A.E.

, Wan

, Law

M.G.

B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS.

AIDS 2000; 14: 133–140.

29.

Lim

S.T.

, Levine

A.M.

Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.

CA Cancer J Clin 2005; 55: 229–241.

30.

Sullivan

R.J.

, Pantanowitz

, Casper

, Stebbing

, Dezube

B.J.

Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Clin Infect Dis 2008; 47: 1209–1215.

31.

Carbone

, Cesarman

, Spina

, Gloghini

, Schulz

T.F.

HIV-associated lymphomas and gamma-herpesviruses.

Blood 2009; 113: 1213–1224.

32.

M.Q.

, Bacon

C.M.

, Isaacson

P.G.

Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.

J Clin Pathol 2007; 60: 1350–1357.

33.

Oksenhendler

, Boulanger

, Galicier

High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.

Blood 2002; 99: 2331–2336.

34.

Chang

, Cesarman

, Pessin

M.S.

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Science 1994; 266: 1865–1869.

35.

Cesarman

, Chang

, Moore

P.S.

, Said

J.W.

, Knowles

D.M.

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

N Engl J Med 1995; 332: 1186–1191.

36.

Hjalgrim

, Engels

E.A.

Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence.

J Intern Med 2008; 264: 537–548.

37.

Ridolfo

A.L.

, Santambrogio

, Mainini

High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma.

AIDS 1996; 10: 181–185.

38.

Biggar

R.J.

, Curtis

R.E.

, Cote

T.R.

, Rabkin

C.S.

, Melbye

Risk of other cancers following Kaposi's sarcoma: relation to acquired immunodeficiency syndrome.

Am J Epidemiol 1994; 139: 362–368.

39.

Engels

E.A.

, Pittaluga

, Whitby

Immunoblastic lymphoma in persons with AIDS-associated Kaposi's sarcoma: a role for Kaposi's sarcoma-associated herpesvirus.

Mod Pathol 2003; 16: 424–429.

40.

Martin-Carbonero

, Palacios

, Valencia

Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.

Clin Infect Dis 2008; 47: 410–417.

41.

Krishnan

, Morgan

G.J.

Non-Hodgkin lymphoma secondary to cancer chemotherapy.

Cancer Epidemiol Biomarkers Prev 2007; 16: 377–380.

42.

Silverberg

M.J.

, Neuhaus

, Bower

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

AIDS 2007; 21: 1957–1963.

43.

Hammer

S.M.

, Eron

J.J.

Jr. , Reiss

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel.

JAMA 2008; 300: 555–570.